Drug Profile
Clarithromycin/clofazimine/rifabutin - RedHill Biopharma
Alternative Names: Clarithromycin/rifabutin/clofazimine; Clofazimine/clarithromycin/rifabutin; Clofazimine/rifabutin/clarithromycin; Myoconda®; RHB 204; RHB-104; Rifabutin/clarithromycin/clofazimine; Rifabutin/clofazimine/clarithromycinLatest Information Update: 29 May 2023
Price :
$50
*
At a glance
- Originator Centre for Digestive Diseases
- Developer RedHill Biopharma
- Class Anti-inflammatories; Antibacterials; Antihyperglycaemics; Antipsoriatics; Antirheumatics; Aza compounds; Ethers; Macrolides; Phenazines; Piperidines; Rifamycins; Skin disorder therapies; Small molecules; Spiro compounds
- Mechanism of Action Adenosine triphosphatase inhibitors; P-glycoprotein inhibitors; Phospholipase A2 inhibitors; Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Crohn's disease; Mycobacterium avium complex infections; Nontuberculous mycobacterium infections
- Phase II Multiple sclerosis
- No development reported Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus; Type 1 diabetes mellitus
Most Recent Events
- 23 May 2023 RedHill Biopharma terminates a phase-III clinical trials in Nontuberculous mycobacterium (Treatment-naïve) infections in USA (PO)
- 26 Jan 2023 Clarithromycin/clofazimine/rifabutin - RedHill Biopharma is available for licensing as of 26 Jan 2023. https://www.redhillbio.com/partnering/default.aspx (9379555; RedHill Biopharma website, January 2023)
- 26 Jan 2023 USPTO issues a Notice of Allowance for the granting of a patent covering RHB 204